Quince Therapeutics (QNCX) news
Recent news
Quince Therapeutics: Leerink Partners adjusts target price to $68 from $4 to reflect 1-for-20 reverse stock split
AInvest Wire · Aug 18, 2026Quince Therapeutics - Brigitte Roberts conditionally appointed as chief executive officer - SEC filing
Quince Therapeutics, Inc. (NASDAQ: QNCX) has announced the conditional appointment of Brigette Roberts, M.D., as Chief Executive Officer, following its acquisition of Orphai Therapeutics, LLC on May 18, 2026, as detailed in a recent SEC filing. Dr. Roberts, who previously served as CEO and Board…
AInvest Wire · Jul 31, 2026Quince Therapeutics - offers 15,470,099 shares of common stock for resale - SEC filing
Quince Therapeutics, Inc. (Nasdaq: QNCX) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of up to 15,470,099 shares of its common stock, according to a recent filing. This includes shares issued in connection with a private placement completed on June 12,…
AInvest Wire · Jul 31, 2026Deckers loses Ugg design patent trial against Quince: Blaw
Deckers Outdoor Corporation, owner of the UGG brand, recently faced a setback in its legal battle with Quince, an affordable fashion e-commerce company. The case, which began in 2023, centered on allegations that Quince’s shearling-lined boots infringed on Deckers’ unregistered trade dress and…
AInvest Wire · Jun 15, 2026Quince Therapeutics Inc. raises $114.7M; offering $186.4M
AInvest Wire · Jun 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.